Clinical Trial of HG146 Administered to Participants With Adenoid Cystic Carcinoma (HG146)
A Phase Il Clinical Study to Evaluate the Efficacy and Safety of HG146 Capsules in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma.
This is a Phase II, open-label, non-randomized, multicenter study to evaluate the clinical efficacy and safety of HG146 in participants with recurrent or metastatic adenoid cystic carcinoma. This study is divided into two stages. 40 participants will be enrolled in the first stage. The efficacy and safty data will apply to make go or no go decision. Then the second stage will continue to enroll 100 Particapants.
研究概览
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:Jie Shen
- 电话号码:8211 8268-85197385
- 邮箱:jie.shen@hitgen.com
学习地点
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国、200000
- 招聘中
- Shanghai Oriental Hospital
-
接触:
- Ye Guo
- 电话号码:8268-85197385
- 邮箱:pattrickguo@gmail.com
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Signed informed consent form (ICF) and able to comply with study.
- Age ≥18 years, gender unlimited.
- Recurrent or metastatic adenoid cystic carcinoma with evidence of disease progression (imaging progression or clinical evidence of progression) within one year of histological or cytological diagnosis.
- Estimated survival >12 weeks, as determined by the investigator.
- The United States Eastern Cancer Consortium (ECOG) physical status score 0-1.
- Has adequate organ function.
- At least 1 measurable tumor lesion according to RECISTv1.1 criteria.
Exclusion Criteria:
- Symptomatic central nervous system (CNS) metastases that have required steroids within 4 weeks prior to first dose of study treatment.
- Received prior therapies targeting HDAC.
- Chemotherapy was received within 21 days before the first administration of the study treatment, and anti-tumor therapy such as radiotherapy, biotherapy, targeted therapy, and immunotherapy was received within 28 days before the first administration of the study treatment [small molecule targeted drugs, Chinese medicines with anti-tumor indications, and local palliative radiotherapy were 14 times before the first administration of the study drug.
- Used strong CYP3A4 inhibitors or inducers within 7 days before the first use of the investigational drug.
- Major surgery or major injury <=28 days before the first dose of study treatment,or anticipated major surgery during the study.
- Prior allogeneic bone marrow transplantation or other solid organ transplantation
- Active infection requiring systemic treatment.
- Current or past presence of other malignancies (other than adequately treated basal cell or squamous cell carcinoma of the skin and carcinoma in situ of the cervix), unless radical treatment has been performed and there is no evidence of recurrence and metastasis in the last 5 years.
- A person is known to be allergic to any active ingredient or excipient of the investigational drug.
- Pregnant or lactating women.
- patients with drug abuse or chronic alcohol abuse that may affect the evaluation of the test results.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Clinical Trial of HG146 Administered to participants with Adenoid cystic carcinoma
Experimental: HG146 Monotherapy Arm Description: Participants will receive HG146 per os at every two days intervals (qod) for 14 consecutive days,7 days off, 21 days/ cycle. |
HG146 is available as Capsule at a unit dose strength of 5 mg and 10 mg.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
objective response rate (ORR)
大体时间:From enrollment to the end of treatment at 4 weeks
|
ORR will be assessed by the investigators using RECIST v1.1 |
From enrollment to the end of treatment at 4 weeks
|
|
6 Months Progression-Free Survival (PFS)
大体时间:From enrollment to treatment at 6 months.
|
PFS will be assessed by the investigators using RECIST v. 1.1 |
From enrollment to treatment at 6 months.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Progression-Free Survival (PFS)
大体时间:From enrollment to treatment at 12 months
|
PFS will be assessed by the investigators using RECIST v1.1 |
From enrollment to treatment at 12 months
|
|
Duration of response (DoR)
大体时间:From enrollment to the end of treatment at 4 weeks
|
DOR will be assessed by the investigators using RECIST v1.1 |
From enrollment to the end of treatment at 4 weeks
|
|
Disease control rate (DCR)
大体时间:From enrollment to the end of treatment at 4 weeks
|
DCR will be assessed by the investigators using RECIST v1.1 |
From enrollment to the end of treatment at 4 weeks
|
|
Overall survival (OS)
大体时间:From enrollment to the end of treatment at 4 weeks
|
OS will be assessed by the investigators |
From enrollment to the end of treatment at 4 weeks
|
|
Time-to-response (TTR)
大体时间:From enrollment to the end of treatment at 4 weeks
|
TTR will be assessed by the investigators using RECIST v1.1 |
From enrollment to the end of treatment at 4 weeks
|
|
Population pharmacokinetics (PopPK)
大体时间:From Cycle1 Day7 to Day13, 21 days per cycle
|
PopPK will be detected to predict exposure level of HG146 in human body. |
From Cycle1 Day7 to Day13, 21 days per cycle
|
合作者和调查者
赞助
调查人员
- 首席研究员:Ye Guo、Shanghai Oriental Hospital
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.